Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Adalimumab
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Adalimumab Amgevita
®
(Ophthalmology)
Eye, Other anti-inflammatory preparations, 11.04.02
RED
Adalimumab Amgevita
®
(Gastroenterology)
Gastro-intestinal system, Cytokine inhibitors, 01.05.03
RED
Adalimumab Amgevita
®
(Rheumatology)
Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
RED
Adalimumab Amgevita
®
(Dermatology)
Skin, Drugs affecting the immune response, 13.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local
BNF
Section
Adalimumab
Adalimumab
Eye, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Allergic And Inflammatory Eye Conditions, Inflammatory Eye Conditions
Adalimumab
Adalimumab
Gastro-Intestinal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Chronic Bowel Disorders, Inflammatory Bowel Disease
Adalimumab
Adalimumab
Musculoskeletal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Arthritis
Adalimumab
Adalimumab
Skin, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Inflammatory Skin Conditions, Eczema And Psoriasis
Adalimumab
Adalimumab
Skin, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Inflammatory Skin Conditions, Hidradenitis Suppurativa
Links found
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA146: Adalimumab for the treatment of adults with psoriasis
NICE TA146: Adalimumab for the treatment of adults with psoriasis
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis